I think based on history, the chances of ARQLs NSCLC pivotal trial being halted and unblinded early are essentially slim to none (much closer to none, than slim)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.